Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Patrick Reville

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID Google Scholar

Research Interests

Pharmacotherapy

50%

Immunology

30%

Hematology

80%

Targeted Therapy

50%

Neoadjuvant Therapy

30%

Oncology

30%

Cancer Biology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

CD38 as a Targetable Antigen in Large B Cell Lymphoma Combined with CD19 CAR T Cells

Open Date: 2022-07-01

Close Date: 2024-06-30

Grant: Close

CD38 as a Targetable Antigen in Large B Cell Lymphoma Combined with CD19 CAR T Cells

Open Date: 2022-04-01

Close Date: 2024-10-31

Articles18

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Article Link

Year:

2025

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Article Link

Year:

2025

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Article Link

Year:

2025

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry

Article Link

Year:

2025

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Article Link

Year:

2025

Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re‐Evaluation of Recommended Dose Adjustments With Azole Antifungals

Article Link

Year:

2025

Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy

Article Link

Year:

2024

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Article Link

Year:

2024

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.

Article Link

Year:

2024

Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation

Article Link

Year:

2024

Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion

Article Link

Year:

2023

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Article Link

Year:

2022

Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment

Article Link

Year:

2022

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Article Link

Year:

2022

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Article Link

Year:

2022

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

Article Link

Year:

2021

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Article Link

Year:

2021

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.

Article Link

Year:

2020

Collaborators16

Cem Meydan

Assistant Professor

Weill Cornell Medicine

UNITED STATES

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES

Caitlin R. Rausch

UNITED STATES

Jayastu Senapati

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Alex Bataller Torralba

The University of Texas MD Anderson Cancer Center

UNITED STATES

Natalia Baran

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Darko Barisic

Assistant Professor

Weill Cornell Medicine

UNITED STATES

Koji Sasaki

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Warren Fiskus

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Fatima Zahra Jelloul

The University of Texas MD Anderson Cancer Center

UNITED STATES

Courtney D. DiNardo

UNITED STATES

Priya Lakra

The University of Texas MD Anderson Cancer Center

UNITED STATES

Mike Collins

Foghorn Therapeutics (United States)

UNITED STATES

Musa Yilmaz

The University of Texas MD Anderson Cancer Center

UNITED STATES

Christopher Ly

The University of Texas MD Anderson Cancer Center

UNITED STATES

Naval G. Daver

The University of Texas MD Anderson Cancer Center

UNITED STATES

How do I reach out?

Meet Kite AI